- Original Article
- Open Access
Magnetic resonance imaging in diagnosis of indeterminate breast (BIRADS 3 & 4A) in a general population
Insights into Imaging volume 12, Article number: 149 (2021)
Currently, mammography and ultrasonography are the most used imaging techniques for breast cancer screening. However, these examinations report many indeterminate studies with a low probability of being malignant, i.e., BIRADS 3 and 4A. This prospective study aims to evaluate the value of breast magnetic resonance imaging (MRI) to clarify the BIRADS categorization of indeterminate mammography or ultrasonography studies.
MRI studies acquired prospectively from 105 patients previously classified as BIRADS 3 or 4A were analyzed independently by four radiologists with different experience levels. Interobserver agreement was determined by the first-order agreement coefficient (AC1), and divergent results were re-analyzed for consensus. The possible correlation between the MRI and the mammography/ultrasound findings was evaluated, and each study was independently classified in one of the five BIRADS categories (BIRADS 1 to 5). In lesions categorized as BIRADS 4 or 5 at MRI, histopathological diagnosis was established by image-guided biopsy; while short-term follow-up was performed in lesions rated as BIRADS 3.
Breast MRI was useful in diagnosing three invasive ductal carcinomas, upgraded from BIRADS 4A to BIRADS 5. It also allowed excluding malignancy in 86 patients (81.9%), avoiding 22 unnecessary biopsies and 64 short-term follow-ups. The MRI showed good diagnostic performance with the area under roc curve, sensitivity, specificity, PPV, and NPV of 0.995, 100%, 83.5%, 10.5%, and 100%, respectively.
MRI showed to be useful as a problem-solving tool to clarify indeterminate findings in breast cancer screening and avoiding unnecessary short-follow-ups and percutaneous biopsies.
MRI exclude malignancy in 81.9% of BIRADS 3 and 4A lesions.
MRI identified three Invasive Ductal Carcinomas by upgrade lesions from BIRADS 4A to 5.
BIRADS scoring of MRI examinations shows moderate/substantial interobserver agreement between radiologists.
MRI has good diagnostic validity in patients with previous examinations categorized as BI-RADS 3 or 4A.
MRI can be considered a tool to clarify indeterminate findings in breast cancer screening.
Breast cancer is the most frequently diagnosed cancer in women and the leading cause of death by cancer among women worldwide . X-ray mammography remains the standard screening method for detecting it in women over 40 years, which has been demonstrated to reduce breast cancer mortality in percentages ranging from 30 to 70% . However, it has variable sensitivity, specificity, and predictive values, which affect its confidence . Likewise, ultrasonography is also used as a screening tool, specially indicated for young and lactating or pregnant women, and as a supplement to mammography screening in women with heterogeneously or extremely dense breasts. This technique presents limitations to detect small lesions and differentiate the cysts with dense contents from solid lesions and be a user-dependent technique . Therefore, imaging alternatives, such as tomosynthesis, contrast ultrasonography, elastography, and magnetic resonance imaging (MRI), have been proposed to replace mammography and ultrasonography as a population screening method [5,6,7,8]. Breast MRI is considered the most sensitive method for detecting breast cancer without the use of ionizing radiation; hence, it has been proposed as an effective screening alternative in the high-risk population [9,10,11,12].
Additionally, the American College of Radiology (ACR) developed the Breast Imaging-Reporting and Database System (BIRADS), which aims to standardize the breast lesion descriptions to reduce the Interobserver variability, to ease the communication with the clinician, and improving the management of the patient. These descriptions aid physicians in deciding the BIRADS category (0 to 6), a value that determines the probability of malignancy and the final management recommendation . BIRADS 3 and 4A categories define most probably benign lesions with malignancy risk less than 2 and 10%, respectively, for which it is advised short-term follow-up imaging or biopsies, which can increase costs for the health system morbidity, and patient anxiety [14, 15].
In cases of indeterminate mammographic and ultrasonographic findings, i.e., lesions rated as BIRADS 3 or 4A, the use of other imaging modalities as “problem-solving” tools has been proposed. Regarding MRI, the American College of Radiology practice guidelines include them under the category of lesion characterization; breast MRI may be indicated when other diagnostic imaging examinations or physical examinations are inconclusive for the presence of breast cancer, and biopsy cannot be performed . However, some studies have suggested that MRI imaging may help the clinician manage BIRADS 3 and 4A lesions and eliminate unnecessary biopsies [16,17,18,19,20,21,22].
The purpose of this single-center study was to prospectively investigate the usefulness of an MRI examination for evaluating lesions detected in mammography or ultrasonography screening that were categorized as BIRADS 3 or 4A from a group of women from a general Latin American female population.
Materials and methods
Study design and population
A prospective study approved by the institutional research and ethical committee was performed between June 2019 and March 2020. The technical staff of Ayudas Diagnósticas Sura (Medellín, Colombia) identified consecutively the patients who were categorized as BIRADS 3 or 4A on mammography and ultrasonography examinations. The identified patients were invited to participate in this prospective study. Those that accepted and met the inclusion criteria were scheduled to undergo the MRI examination following the institutional protocol. Informed consent was obtained from each patient.
Patients were considered eligible when they were over 18 years old and had examinations categorized as BIRADS 3 or 4A (ACR BIRADS® Atlas Fifth Edition) at mammography, ultrasonography or both during the last year. Patients with pacemakers, nonremovable drilling at the nipple or other devices in the chest wall, unable to keep upright immobility, claustrophobic or allergic to the contrast medium; or with a confirmed diagnosis of breast cancer, or history of carcinoma in situ, were excluded. All patients underwent the same MRI protocol, regardless of the finding for which they were referred.
The mammography and ultrasonography examinations were acquired and interpreted in service outside the institutions participating in this research. The radiological reports were requested from the participants during recruitment and archived for later use. For this reason, there was no control or follow-up on the acquisition or interpretation protocols of those examinations. All patients underwent a breast MRI protocol with a 1.5 T Philips resonator with a 7-channel breast dedicated coil. The patient was in the prone position. Examinations were scheduled on the second week of the menstrual cycle in premenopausal women, and no scheduling limitations were defined for postmenopausal women. The MRI protocol is described in Table 1. It encompassed one Axial T1-weighted non-fat-saturated sequence, followed by an Axial diffusion-weighted sequence with B0 and B 800 factors. For the dynamic contrast enhancement assessment, one unenhanced fat-suppression T1 sequence and six volumetric SPIR T1W High-Resolution Isotropic Volume Examination (THRIVE) sequences were acquired after the injection of meglumine gadoterate at a dose of 0.2 mL/kg (0.1 mmol/kg).
The contrast medium was injected with an injector at a 2.5 ml/s rate with yelco infusion number 20. Subsequently, an Axial T2-weighted fast spin-echo (3D VISTA) without fat saturation and a coronal STIR sequence were acquired. When the patient had breast implants, the short tau inversion recovery (STIR) sequence was replaced by a T2 coronal fat suppression 3d VISTA to better contrast with the silicone (FOV 300 × 364 × 200, matrix 252 × 256, repetition time 7010, echo time 80, duration 3:16 min). Finally, the imaging technologist performs the subtraction of the dynamic sequences, obtains the color perfusion maps, and generates the Apparent Diffusion Coefficient (ADC) map. The images are sent to the PACS and the Invivo post-processing station for future interpretation.
MRI examinations were initially prospectively interpreted by one breast imaging radiologist (R1) with 12 years of experience interpreting breast MRI examinations. A computer-aided diagnosis (CAD) program (DynaCAD Philips, Inc.) was available for breast interpretation; however, its use was decided at the discretion of the interpreting radiologist. Then, all examinations were retrospectively and independently analyzed by three radiologists with 10 (R2), 5 (R3) and less than one (R4) years of experience (caseload ranging between 100 and 200 breast MRI examinations per year). The less experienced radiologist (R4) was one experienced mammogram reader (> 10 years) who was trained to interpreting the MRI scans. These radiologists were blinded to any concept of the others.
According to the location, size, and morphological characteristics, each radiologist evaluated a possible correlation between the MRI and mammography/ultrasonography findings reported by previous examinations. Additionally, radiologists evaluated the mammary tissue composition, the background physiological enhancement, the uptake asymmetry, the positive findings, and morphological and kinetic characteristics; they also determined the presence of tissue restriction given by the ADC value, the associated and incidental findings. According to the fifth version of the BIRADS lexicon, breasts were classified as A, B, C or D density categories; and minimal, mild, moderate, or marked background parenchymal enhancement; for the positive findings, in the case of the masses, the shape, margins and internal characteristics were described; and in the case of non-mass enhancements, the distribution and internal features were described. Post-gadolinium kinetic curve analysis was referred to as persistent, plateau, or wash-out pattern. Additionally, the associated findings evaluated the involvement of the skin or muscles and lymphadenopathy in internal or axillary mammary chains.
Once MRI findings have been identified, radiologists assign a category according to BIRADS fifth edition, based on the imaging features and other available information as previous breast imaging studies and the patient’s clinical history. Following institutional practice, radiologists were asked to follow the Kaiser scoring system. It is a simple decision rule-based flowchart that guides readers to a clinical decision about the risk of malignancy (scores from 1 to 11) by characterizing five specific diagnostic criteria, i.e., root sign(present/ absent), delayed enhancement curve type (persistent/ plateau/ wash-out), margins (smooth/ irregular), internal enhancement pattern (inhomogeneous/ homogeneous) and edema (diffuse ipsilateral or perifocal/ absent or diffuse bilateral) [23, 24]. The resulting score is translated into the BI-RADS categories that are finally reported . Nevertheless, final categorizations were done at the discretion of the interpreting radiologist. The results were stored in a referential database to facilitate future consultation.
Divergent results were re-analyzed by the most experienced reviewers in consensus. According to the BIRADS lexicon, breasts with normal or benign findings fall into BIRADS 1 or 2 categories and continue the usual screening process; BIRADS 3 lesions are those that are probably benign, with a risk of malignancy less than 2%. These lesions require a short-term follow-up for up to two years to confirm their progress, stability, or regression. BIRADS 4 lesions have attributed risk of malignancy between 2 and 95%, and like BIRADS 5 lesions, which carry a risk of malignancy greater than 95%, they are always biopsied.
All patients with MRI findings categorized as BIRADS 4 or 5 underwent biopsy. Histologic sampling was performed under ultrasonography or mammography imaging guidance depending on which method was best suited to locate and access the lesion. Patients with MRI examinations classified as BIRADS 3 underwent short follow-up, by at least one year, with mammography, ultrasonography, or MRI to check the stability of the findings. Patients with MRI examinations classified as BIRADS 2 were requested to perform clinical examinations. In cases that were required, new imaging tests were also performed.
Considering BI-RADS 3 to 5 as positive findings and 1 and 2 as negative, the sensitivity, specificity, positive predictive values (PPV) and negative predictive values (NPV) with 95% confidence intervals (CI) were calculated. Overall accuracy was evaluated based on the receiver operating characteristic (ROC) analysis and the area under the curve (AUC) calculation.
On the other hand, the Interobserver agreement was calculated using the generalized kappa  and the first-order agreement coefficient (AC1) proposed by Gwet . As Wongpakaran et al.  shown, it is not affected by the prevalence of the phenomenon under study. Breast cancer tumors were considered malignant, and all other histologic diagnoses and stable follow-up were considered as the absence of malignancy.
Figure 1 provides the study patient selection flowchart. Between June 2019 and January 2020, 130 women with a previous breast image examination (mammography or ultrasonography) ranked as BIRADS 3 or 4A were invited to participate in this study. A total of 107 subjects agreed to participate, but two were determined to be ineligible; the first was due to previous examination results being larger than one year, and the second was due to errors in the acquisition protocol. Thus, 105 eligible patients were finally enrolled; 71 (67.62%) of them presented examinations categorized as BIRADS 3 and 34 (32.38%) as BIRADS 4A. Previous examinations were ultrasonography for 81 patients (82.85%), mammography for 11 patients (10.47%), and both ultrasonography and mammography for 13 patients (12.38%). A total of 282 findings were reported in previous examinations, 181 (64.18%) in examinations classified as BIRADS 3, and 101 (35.81%) in BIRADS 4A exams. All subjects underwent a Breast MRI examination before continuing with defined management, i.e., imaging follow-up or percutaneous biopsy. Time elapsed between the previous imaging and the MRI was 155.6 ± 117.5 (mean ± Standard Deviation) and 41.8 ± 26.79 days for previous BIRADS 3 and BIRADS 4A exams, respectively.
All patients were Colombian women, ranging from 20 to 70 years old with a mean age of 42.71 ± 11.15. Table 2 presents a summary of the demographic data of participants. Among 25 (23.8%) patients with previous histological proven benign findings, 18 were fibroadenoma, one an adenosis, one a cystic fibrosis, one a fibrocystic mastopathy, one a ductal hyperplasia, one a fat necrosis, and two were epidermal inclusion cysts. Two patients also had a history of breast cancer greater than five years. (in situ ductal carcinoma). Regarding family history, nine patients had a first-degree relative (mother), 11 had a second-degree relative (six grandmothers and five sisters), and two had a history of both first and second-degree relative (mother and grandmother). There were 68 premenopausal (64.8%) and 38 postmenopausal (35.2%) patients. For postmenopausal patients, the mean years past since the last menstruation was 8.4 ± 6.01 (range, 1–26 years), three patients were subjected to hysterectomy.
After the consensus of radiologists, a total of 308 findings were identified at the MRI examinations. From these, 191 were found in examinations performed on patients enrolled as BIRADS 3, and the other 117 were found at the MRI exams of patients with previous images categorized as BIRADS 4A. Table 3 shows a summary of the main imaging features of those findings. From 105 examinations, 11.4% showed minimal background parenchymal enhancement (BPE); 36.2%, mild; 34.3%, moderate; and 18.1%, marked enhancement. In the group with minimal BPE, only one examination was classified as BIRADS 3 due to a suspicious nodule not being seen in previous examinations. The other BIRADS 3, 4 or 5 examinations corresponded to mild (44%), moderate (33%) and marked (17) BPE. On the other hand, breast density was high (ACR C or D) in a total of 81 patients (77.1%), which was expected because they had BIRADS 3 and 4A examinations. Less than half of the described findings showed contrast enhancement (49.3%). Thus, among 152 enhanced lesions, 102 (65.4%) were mass, 4 (2.7%) were non-mass enhancements, and 46 (29.5%) corresponded to another kind of lesions such as cyst, Intramammary ganglion, among others. The kinetic curve for mass and non-mass enhancements was persistent in 87 lesions (82%), plateau in 16 (15.1%) and wash-out in three of them (2.8%). Table 4 summarizes the findings reported at MRI examinations. Most of them were nodules (52.27%) or simple cysts (27.9%). Additionally, nine associated findings were identified, as reported in Table 5.
MRI outcome of previous mammographic and ultrasonographic findings
The possible correlation between the MRI and mammography/ultrasonography findings for BIRADS 3 and 4A admitted studies are presented in Tables 5, 6, 7 and 8, respectively. A total of 282 findings were described in previous mammography and ultrasonography examinations. From them, 46 were not visualized at the MRI examinations. The most frequent mammographic and ultrasonography findings reported in BIRADS 3 were circumscribed solid nodules, multiple nodules, complicated cysts, and asymmetries; they were correlated at MRI with solid non-enhanced nodules, solid nodules with persistent enhancement, and cysts (Tables 5 and 6). The most frequent findings from previous BIRADS 4A were circumscribed nodules and multiple nodules, correlated with solid nodules with persistent enhancement (Tables 7, 8) at MRI.
On the other hand, 72 incidental MRI findings were identified, 39 in patients previously categorized as BIRADS 3 and 33 as BIRADS 4A. These were: 26 nodules, 27 simple cysts, 4 clusters of microcysts, two hemorrhagic cysts, eight intramammary ganglions, three ductal ectasias, one fat necrosis, and one von Meyenburg complex (multiple biliary hamartomas). However, none of these findings was identified as malignant.
Figures 2, 3, 4, 5, 6, 7 and 8 present MRI images examples of representative findings categorized as BIRADS 3 or 4A by previous mammography or ultrasonography examinations. Figure 2 presents the most typical and easy-decision case; it is a non-enhancing lesion (Kaiser Score 0 / BIRADS 2). Among 184 nodules reported in the previous examinations of recruited patients, 67 (35%) did not show contrast enhancement; thus, these lesions were downgraded to BIRADS 2 i.e., benign lesions. Figures 3 and 4 show examples of some contrast-enhanced lesions with circumscribed margins, persistent signal enhancement time curves, and no restricted diffusivity, features compatible with benign findings (BIRADS-2). Figure 4. Illustrates the advantage of MRI scans in presence of multiple findings; 3D analysis and contrast enhancement are useful in those cases. Figure 5 shows an example of hamartoma, a benign lesion that presents varying amounts of benign epithelial components, fibrous tissue, and fat tissue. Figures 6 and 7 show examples of false positives cases, i.e., benign lesions categorized as BIRADS 4. Two cases describing imaging features of low risk of malignancy (Kaiser score 2) but were biopsy recommended due to size increasing of the lesions. Finally, Fig. 8 shows an example of a malignant, categorized as BIRADS 5, which presents irregular contours with superior external spiculations and a homogeneous enhancement, with a wash-out pattern and ADC value of 0.8 × 10−3mm2/s.
Among 105 patients, 71 (67.62%) were admitted for having a previous BIRADS 3 imaging examination, and 34 (32.38%) for having BIRADS 4A. Table 9 presents the mammographic and ultrasonographic findings that determined the BIRADS examination category and their respective classification on the MRI examination. Although 282 findings were described in the previous examinations, 131 were decisive for establishing the BIRADS category: 88 from BIRADS 3 and 43 from BIRADS 4A examinations. The mammographic findings that led to a BIRADS 3 categorization were asymmetries (n = 9), single nodules (n = 4), multiple nodules (n = 1), and microcalcifications (n = 1), while the ultrasonography findings were: solid nodule (n = 36), multiple nodules (n = 17), complicated cyst (n = 13), accumulation of microcysts (n = 5), ductal ectasia (n = 1) and asymmetry (n = 1). On the other hand, for BIRADS 4A patients, the mammographic findings were asymmetry (n = 2), nodule (n = 3), multiple nodules (n = 2), and segmental calcifications (n = 1), and the ultrasonography findings were solid nodules (n = 27), multiple nodules (n = 1), ductal ectasia (n = 3), asymmetry (n = 2), complex cyst (n = 1) and intraductal papilloma (n = 1).
Among 71 patients included as category BIRADS 3, 64 (90.14%) were re-classified on category BIRADS 1 or 2, which means that they can continue the conventional biannual screening; 3 continued in category BIRADS 3, but they have remained stable in the follow-ups, and four were upgrades to BIRADS 4 and underwent percutaneous biopsy, all of them resulting in fibroadenoma. Additionally, among 34 patients previously categorized as BIRADS 4A, 22 (64.7%) were recategorized as BIRADS 1 or 2; four (11.76%) as BIRADS 3, who have remained with stable lesions in follow-up; five (14.7%) remained as BIRADS 4, with benign histological analyzes (two fat necrosis, two fibroadenomas, and one canalicular fibroadenoma); and three (8.8%) patients were recategorized as BIRADS 5, these with malignant histology.
Finally, 86 (81.9%) subjects were downgraded to BIRADS 1 or 2, which means that 64.7% (22) biopsies and 90.1% (64) short-term follow-ups were avoided. Eight patients (7.61%) were categorized as BIRADS 3 and considered negative cases due to no changes after short-term follow-up; 9 (8.41%) subjects were categorized as BIRADS 4 (three of them upgraded from BIRADS-3 lesions), and 3 were upgraded to BIRADS 5 (2.8%). However, only the three BIRADS 5 lesions were breast cancer diagnosed (Invasive Ductal Carcinoma), and the nine BIRADS 4 as benign lesions.
Considering BI-RADS 3 to 5 as positive findings and 1 and 2 as negative, Fig. 9 presents the receiver operating characteristic curves (ROC) for each radiologist and the consensual decision (CS). Likewise, Table 10 presents the area under the roc curve (AUC), sensitivity, specificity, and positive and negative predictive values. For the consensual decision, ROC analysis revealed an area under the ROC curve of 0.995 (95% CI: 0.986–1.00), three true-positive, 94 true negatives, 9 false positives, and no false-negative cases. Eight false positives were categorized as BI-RADS 4, and the other eight as BI-RADS 3. The sensitivity, specificity, positive and negative predictive values were calculated as 100%, 83.5%, 10.5%, and 100%, respectively. Note that the small number of positive cases limits the statistical analysis of sensitivity and PPV results.
Regarding radiologist experience, AUC increase from less (R4) to most (R1) experienced radiologist. Four radiologists identify the three malignant lesions, although R3 and R4 assigned a category BIRADS 4 to two of them. Specificity was significantly lower for the less experienced radiologist (R4); however, the most experienced was not the best performer. A detailed review of the results shows that she assigned BIRADS 3 category to some studies that presented image characteristics compatible with benignity but presented some differences with the findings reported in previous studies.
Table 11 presents the generalized kappa and the AC1 between radiologists. As was expected, the AC1 statistics always lead to higher values than kappa statistics. According to Landis and Koch’s benchmark scale , the overall interobserver agreement given by the kappa coefficient of 0.207 indicated a fair agreement; however, AC1 showed a substantial agreement (0.65). Best concordance was observed between the two radiologists with intermediate experience (R2, R3: 0.80), while the greatest differences were reported between the two radiologists with the major experience and the one with the least (R1, R4: 0.56 and R2, R4: 0.57); however, moderate, and substantial agreements were obtained for all cases.
BIRADS 3 and 4A lesions are known to have a small probability of being malignant (less than 2% and 10%, respectively). In order to exclude malignancy, BIRADS 3 lesions are short followed, while BIRADS 4A undergo percutaneous biopsy. It can result in many unnecessary exams, but it could also delay the detection of malignant lesions.
Hence, in recent years, diagnostic methods such as tomosynthesis, elastography, contrast mammography, and magnetic resonance imaging have been proposed, combined with mammography and ultrasonography, to reduce diagnostic uncertainty, save follow-ups and avoid morbid and expensive invasive procedures [30, 31]. Breast MRI examinations that include dynamic contrast-enhanced sequences allow the evaluation of the kinetic and morphological characteristics of the lesions, which cannot be adequately characterized by ultrasonography or mammography, proving to be useful for differentiating benign from probably malignant lesions.
In this study, breast MRI findings of 105 patients, with previous mammography or ultrasonography examinations classified as BIRADS 3 or 4A were compared. Histopathology revealed three invasive ductal carcinoma lesions, resulting in a prevalence of malignancy of 2.8%. The sensitivity of breast-MRI was 100%, the specificity was 83.5% (75.0–89.5%), PPV was 10.5%, and NPV was 100%. The small number of positive cases limits the statistical analysis and the power of sensitivity results. However, as this study focused on determining whether the breast MRI examination allows excluding malignancy for reducing unnecessary biopsies or short follow-ups, we compute the power sample size for specificity. It was 80%, with a significance level of 0.05, a core needle biopsy specificity of 0.98  and a breast MRI specificity of 0.85, according to previous studies for inconclusive mammography or ultrasonography cases (62.4–97%) [10, 18, 33,34,35,36,37]. In this study, BIRADS category 3 was defined as a positive finding due to that it remains a small risk of malignancy (less than 2%), which generates lower specificity concerning the obtained if these cases were considered negative or benign results, as in other studies [33, 35, 37].
Regarding detected lesions, among 282 findings reported at previous imaging examinations, 120 (41.6%) were identified as benign by their kinetic characteristics; 67 of them (55.8%) due that they do not enhance with the contrast medium; and present morphological characteristics that allow characterizing it as benign findings such as asymmetries, cysts, and ductal ectasias. On the other hand, breast MRI was useful in diagnosing three invasive ductal carcinomas, categorized as BIRADS 5, which would prioritize the percutaneous biopsy performing, enhancing the diagnosis and treatment opportunity for these patients. Additionally, MRI helped identify other breast and associated lesions not previously visualized in the other imaging modalities. Although none of them turned out to be a malign finding, this shows the ability of MRI to identify lesions hidden for other modalities. Nevertheless, MRI fails to represent several findings described from other imaging examinations, including microcalcifications observed in mammography. It seems to indicate that MRI may help resolve indeterminate cases in screening with other imaging techniques; however, its use as an individual screening method was outside the scope of this study.
Altogether, malignancy was excluded in 86 patients (81.9%), avoiding 22 (64.7%) of unnecessary biopsies and 64(90.1%) of short-term follow-ups. Three BIRADS 3 lesions (4.2%) were upgraded to BIRADS 4, causing unnecessary immediate biopsies; four BIRADS 4 (11.7) were downgraded to BIRADS 3, which implies a reduction in the number of unnecessary biopsies, but a delay in the diagnostic conclusion. Three BIRADS 4 patients (8.82%) were upgraded correctly to BIRADS 5. Therefore, as was previously reported [36,37,38], in this study, MRI showed to be very useful for downgrading the BIRADS category from indeterminate (BIRADS 3 or 4A) to normal or benign findings (BIRADS 1 or 2). It entails physical and psychological benefits to patients and savings for health systems by increasing the time for breast imaging follow-up and preventing unnecessary percutaneous biopsies.
On the other hand, although differences between radiologists were not statistically significant, this study showed a greater concordance between the findings reported by radiologists who are experts in the interpretation of breast MRI examinations than those with less experience. Specifically, the radiologist with less experience has greater difficulties in distinguishing benign findings, even when the Kaiser score was used, as was reported in previous studies .
This study has some limitations. First, only those examinations categorized as BIRADS 4 or 5 at MRI have undergone a biopsy because it was considered unnecessary to biopsy on lesions that showed characteristics of benignity at MRI, i.e., BIRADS 1 to 3. In those cases, the reference standard was the short follow-up result, which is considered an imperfect standard that could bias the diagnostic performance. Second, the number of included patients is not extensive; it does not include enough cases of interest, such as patients with microcalcifications or architectural distortion. One study with those specific characteristics could establish the effect of using MRI to solve indeterminate results in those cases. Third, the Kaiser score flowchart was not systematically carried out, and either was it recorded. It avoided to evaluating their effect on the reported results. It has been shown to be relevant in recent studies [39,40,41], which should be considered in future works. And fourth, the cost-effectiveness of the MRI relative to continue with the management defined by previous examinations was not calculated, due precisely to the first limitation described above. It is important because one of the main barriers to implementing MRI in diagnosing breast cancer is its high cost. However, our results allow us to suppose that the abbreviated protocols, recently proposed in the literature [42, 43], could be equally useful in these cases. Because the BIRADS category of most of the findings was resolved by morphological analysis or by the absence of contrast enhancement, which can be observed in early sequences of DCE, the use of abbreviated protocols could improve the cost-effectiveness of using MRI as a problem-solving tool in breast cancer screening.
In conclusion, this study shows the feasibility of using Breast MRI to clarify the interpretation of lesions classified as BIRADS3 and 4A on conventional medical imaging, i.e., mammography and ultrasonography. It can downgrade up to 86% of lesions for excluding malignancy, which could avoid unnecessary biopsies and short-term follow-ups in a substantial number of cases.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
First-order agreement coefficient
American College of Radiology
Apparent diffusion coefficient
Area under ROC curve
Breast Imaging-Reporting and Database System
Instituto de Alta Tecnología Médica
Magnetic resonance imaging
Negative predictive values
Positive predictive values
Receiver operating characteristic
Spectral presaturation with inversion recovery
Short tau inversion recovery
T1W high-resolution isotropic volume examination
3D volume isotropic turbo spin-echo acquisition (Philips)
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424
Kuhl CK, Schrading S, Leutner CC et al (2005) Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 23(33):8469–8476. https://doi.org/10.1200/JCO.2004.00.4960
Halladay JR, Yankaskas BC, Bowling JM, Alexander C (2010) Positive predictive value of mammography: comparison of interpretations of screening and diagnostic images by the same radiologist and by different radiologists. AJR Am J Roentgenol 195(3):782–785. https://doi.org/10.2214/AJR.09.2955
Yang L, Wang S, Zhang L et al (2020) Performance of ultrasonography screening for breast cancer: a systematic review and meta-analysis. BMC Cancer 20:1–15. https://doi.org/10.1186/s12885-020-06992-1
Basha MAA, Safwat HK, Eldin AMA, Dawoud HA, Hassanin AM (2020) The added value of digital breast tomosynthesis in improving diagnostic performance of BI-RADS categorization of mammographically indeterminate breast lesions. Insights Imaging 11(1):1–12. https://doi.org/10.1186/s13244-020-0835-2
Zhang XL, Guan J, Li MZ et al (2016) Adjunctive targeted contrast-enhanced ultrasonography for the work-up of Breast Imaging Reporting and Data System category 3 and 4 lesions. J Med Imaging Radiat Oncol 60(4):485–491. https://doi.org/10.1111/1754-9485.12466
Liu G, Zhang MK, He Y, Liu Y, Li XR, Wang ZL (2019) BI-RADS 4 breast lesions: could multi-mode ultrasound be helpful for their diagnosis? Gland Surg 8(3):258. https://doi.org/10.21037/GS.2019.05.01
Wang M, Yang Z, Liu C et al (2017) Differential diagnosis of breast category 3 and 4 nodules through BI-RADS classification in conjunction with shear wave elastography. Ultrasound Med Biol 43(3):601–606. https://doi.org/10.1016/j.ultrasmedbio.2016.10.004
Mainiero MB, Moy L, Baron P et al (2017) ACR appropriateness Criteria® breast cancer screening. J Am Coll Radiol 14(11):S383–S390. https://doi.org/10.1016/j.jacr.2017.08.044
Mann RM, Kuhl CK, Moy L (2019) Contrast-enhanced MRI for breast cancer screening. J Magn Reson Imaging 50(2):377–390. https://doi.org/10.1002/jmri.26654
Narayan AK, Visvanathan K, Harvey SC (2016) Comparative effectiveness of breast MRI and mammography in screening young women with elevated risk of developing breast cancer: a retrospective cohort study. Breast Cancer Res Treat 158(3):583–589. https://doi.org/10.1007/s10549-016-3912-y
Leithner D, Wengert GJ, Helbich TH et al (2018) Clinical role of breast MRI now and going forward. Clin Radiol 73(8):700–714. https://doi.org/10.1016/j.crad.2017.10.021
Gilbert FJ, Warren RML, Kwan-Lim G et al (2009) Cancers in BRCA1 and BRCA2 carriers and in women at high risk for breast cancer: MR imaging and mammographic features. Radiology 252(2):358–368. https://doi.org/10.1148/radiol.2522081032
Clauser P, Bazzocchi M, Marcon M, Londero V, Zuiani C (2017) Results of short-term follow-Up in BIRADS 3 and 4a breast lesions with a histological diagnosis of fibroadenoma at percutaneous needle biopsy. Breast Care 12(4):238–242. https://doi.org/10.1159/000477536
Flowers CI, O’Donoghue C, Moore D et al (2013) Reducing false-positive biopsies: A pilot study to reduce benign biopsy rates for BIRADS 4A/B assessments through testing risk strati cation and new thresholds for intervention. Breast Cancer Res Treat 139(3):769–777. https://doi.org/10.1007/s10549-013-2576-0
American College of Radiology and others (2018) ACR practice parameter for the performance of contrast-enhanced magnetic resonance imaging (MRI) of the breast
Cohen E, Leung JWT (2018) Problem-solving MR imaging for equivocal imaging findings and indeterminate clinical symptoms of the breast. Magn Reson Imaging Clin N Am 26(2):221–233. https://doi.org/10.1016/j.mric.2017.12.012
Taskin NF, Polat Y, Erdogdu H, Turkdogan FT, Ozturk VS, Ozturk S (2018) Problem-solving breast MRI: useful or a source of new problems? Diagnos Intervent Radiol 24(5):255–261. https://doi.org/10.5152/dir.2018.17504
Spick C, Szolar DHM, Preidler KW et al (2018) 3 Tesla breast MR imaging as a problem-solving tool: Diagnostic performance and incidental lesions. PLoS One 13(1):1–12. https://doi.org/10.1371/journal.pone.0190287
Avendano D, Marino MA, Onishi N et al (2020) Can follow-up be avoided for probably benign US masses with no enhancement on MRI? Eur Radiol 31(2):975–982. https://doi.org/10.1007/s00330-020-07216-7
Amitai Y, Scaranelo A, Menes TS et al (2020) Can breast MRI accurately exclude malignancy in mammographic architectural distortion? Eur Radiol 30(5):2751–2760. https://doi.org/10.1007/s00330-019-06586-x
Turk G, Ozdemir M, Coban M, Koc A (2020) Is biopsy necessary? Role of DCE-MRI in BIRADS-3 lesions. Diagn Interv Radiol 26(6):552. https://doi.org/10.5152/dir.2020.19455
Baltzer PA, Dietzel M, Kaiser WA (2013) A simple and robust classification tree for differentiation between benign and malignant lesions in MR-mammography. Eur Radiol 23(8):2051–2060. https://doi.org/10.1007/s00330-013-2804-3
Marino MA, Clauser P, Woitek R et al (2016) A simple scoring system for breast MRI interpretation: does it compensate for reader experience? Eur Radiol 26(8):2529–2537. https://doi.org/10.1007/s00330-015-4075-7
Dietzel M, Baltzer PAT (2018) How to use the Kaiser score as a clinical decision rule for diagnosis in multiparametric breast MRI: a pictorial essay. Insights Imaging 9(3):325–335. https://doi.org/10.1007/s13244-018-0611-8
Fleiss JL (1971) Measuring nominal scale agreement among many raters. Psychol Bull 76(5):378–382. https://doi.org/10.1037/h0031619
Gwet KL (2014) Handbook of inter-rater reliability: the definitive guide to measuring the extent of agreement among raters. Advanced Analytics, LLC
Wongpakaran N, Wongpakaran T, Wedding D, Gwet KL (2013) A comparison of Cohen’s Kappa and Gwet’s AC1 when calculating inter-rater reliability coefficients: a study conducted with personality disorder samples. BMC Med Res Methodol 13(1):1–7. https://doi.org/10.1186/1471-2288-13-61
Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33(1):159. https://doi.org/10.2307/2529310
Li E, Li J, Song Y, Xue M, Zhou C (2014) A comparative study of the diagnostic value of contrast-enhanced breast MR imaging and mammography on patients with BIRADS 3–5 microcalcifications. PLoS One 9(11):e111217. https://doi.org/10.1371/journal.pone.0111217
Ali EA, Adel L (2019) Study of role of digital breast tomosynthesis over digital mammography in the assessment of BIRADS 3 breast lesions. Egypt J Radiol Nucl Med 50(1):1–10. https://doi.org/10.1186/s43055-019-0052-5
Wang M, He X, Chang Y, Sun G, Thabane L (2017) A sensitivity and specificity comparison of fine needle aspiration cytology and core needle biopsy in evaluation of suspicious breast lesions: a systematic review and meta-analysis. Breast 31:157–166. https://doi.org/10.1016/j.breast.2016.11.009
Spick C, Szolar DH, Preidler KW, Tillich M, Reittner P, Baltzer PA (2015) Breast MRI used as a problem-solving tool reliably excludes malignancy. Eur J Radiol 84(1):61–64. https://doi.org/10.1016/j.ejrad.2014.10.005
Giess CS, Chikarmane SA, Sippo DA, Birdwell RL (2017) Clinical utility of breast MRI in the diagnosis of malignancy after inconclusive or equivocal mammographic diagnostic evaluation. AJR Am J Roentgenol 208(6):1378–1385. https://doi.org/10.2214/AJR.16.16751
Shimauchi A, Machida Y, Maeda I, Fukuma E, Hoshi K, Tozaki M (2018) Breast MRI as a problem-solving study in the evaluation of BI-RADS categories 3 and 4 microcalcifications: is it worth performing? Acad Radiol 25(3):288–296. https://doi.org/10.1016/j.acra.2017.10.003
Dorrius MD, Pijnappel RM, Sijens PE, van der Weide MCJ, Oudkerk M (2012) The negative predictive value of breast Magnetic Resonance Imaging in noncalcified BIRADS 3 lesions. Eur J Radiol 81(2):209–213. https://doi.org/10.1016/j.ejrad.2010.12.046
Strobel K, Schrading S, Hansen NL, Barabasch A, Kuhl CK (2015) Assessment of BIRADS category 4 lesions detected with screening mammography and screening US: utility of MR imaging. Radiology 274(2):343–351. https://doi.org/10.1148/radiol.14140645
Turnaoglu H, Ozturk E, Yucesoy C et al (2018) Can breast magnetic resonance imaging prevent biopsy or change the management of BIRADS® category 4 breast lesions? Indian J Surg 80(5):505–512. https://doi.org/10.1007/s12262-017-1654-7
Jajodia A, Sindhwani G, Pasricha S et al (2021) Application of the Kaiser score to increase diagnostic accuracy in equivocal lesions on diagnostic mammograms referred for MR mammography. Eur J Radiol 134:109413. https://doi.org/10.1016/j.ejrad.2020.109413
Woitek R, Spick C, Schernthaner M et al (2017) A simple classification system (the Tree flowchart) for breast MRI can reduce the number of unnecessary biopsies in MRI-only lesions. Eur Radiol 27(9):3799–3809. https://doi.org/10.1007/s00330-017-4755-6
Milos RI, Pipan F, Kalovidouri A et al (2020) The Kaiser score reliably excludes malignancy in benign contrast-enhancing lesions classified as BI-RADS 4 on breast MRI high-risk screening exams. Eur Radiol 30:6052–6061. https://doi.org/10.1007/s00330-020-06945-z
Kuhl CK (2019) Abbreviated magnetic resonance imaging (MRI) for breast cancer screening: rationale, concept, and transfer to clinical practice. Annu Rev Med 70(1):501–519. https://doi.org/10.1146/annurev-med-121417-100403
Hernandez ML, Osorio S, Florez K, Ospino A, Díaz GM (2020) Abbreviated magnetic resonance imaging in breast cancer: a systematic review of literature. Eur J Radiol Open 8:100307. https://doi.org/10.1002/jmri.26339
Authors acknowledge to the staff of the IATM Research Group for its technical support in the MRI image database acquisition and analysis.
This work was funded by the Ministry of Science, Technology, and Innovation—MinCiencias (Colombia), Instituto Tecnológico Metropolitano, and Ayudas Diagnósticas Sura. Project RC740-2017.
Ethics approval and consent to participate
Institutional review board of the Instituto de Alta Tecnología Médica (CIE-IATM) approval was obtained. Written informed consent was obtained from all participants.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Hernández, L., Díaz, G.M., Posada, C. et al. Magnetic resonance imaging in diagnosis of indeterminate breast (BIRADS 3 & 4A) in a general population. Insights Imaging 12, 149 (2021). https://doi.org/10.1186/s13244-021-01098-z
- Breast cancer
- Indeterminate lesions
- Magnetic resonance imaging